Fig. 1: Elevated NCOA5 expression correlates with poor prognosis and sorafenib resistance in hepatocellular carcinoma (HCC).
From: NCOA5 induces sorafenib resistance in hepatocellular carcinoma by inhibiting ferroptosis
A, B Violin, box, and dot plots illustrating NCOA5 expression levels in the TCGA HCC dataset (TCGA-LIHC), comparing HCC tissues with peri-tumoral liver tissues. C RT-qPCR assays demonstrating mRNA levels of SNCOA5 and non-SNCOA5 in 15 HCC patient samples and their corresponding adjacent normal tissues. ***P < 0.001 by Student’s t-test. D Representative immunohistochemistry (IHC) images showing NCOA5 expression in HCC tissues versus paired adjacent normal tissues (left panel). Statistical analysis comparing IHC scores of 78 HCC tissues with their paired normal tissues (right panel). E Receiver operating characteristic (ROC) curve illustrating the overall survival (OS) predictive value of NCOA5 in 78 HCC patients. The area under the curve (AUC) is 0.727. The diagonal black line depicts a reference AUC of 0.5. F Kaplan-Meier analysis indicating the correlation between NCOA5 expression and OS in 78 HCC patients (P = 0.021 by log-rank test). G Distribution of risk scores and rank statistics generated from Kaplan-Meier analysis using the TCGA HCC dataset. H Kaplan-Meier analysis demonstrating significantly higher OS rates in the low-NCOA5 group compared to the high-NCOA5 group (P < 0.001 by log-rank test) using the TCGA HCC dataset. I, J Dot, box, and distribution plots showing NCOA5 expression in the publicly available GEO HCC datasets (left panels; I, GSE109211; J, GSE182593), comparing HCC patients who received sorafenib therapy, distinguishing between responders and non-responders. *P < 0.05, **P < 0.01 by Student’s t-test. Percentage of samples showing sorafenib responders or nonresponders relative to NCOA5 levels in HCC tissues (right panels; I, GSE109211; J, GSE182593). *P < 0.05 and ***P < 0.001 by χ² test. K Representative IHC images showcasing the differential expression of NCOA5 in HCC tissues of sorafenib responders versus non-responders (left panel). Statistical analysis showing the percentage of samples of sorafenib responders or non-responders relative to NCOA5 levels in HCC tissues (n = 60). ***P < 0.001 by χ2 test.
